Tenax Therapeutics is a biotechnology business based in the US. Tenax Therapeutics shares (TENX) are listed on the NASDAQ and all prices are listed in US Dollars. Tenax Therapeutics employs 5 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.37 |
|---|---|
| 52-week range | $2.77 - $57.58 |
| 50-day moving average | $3.35 |
| 200-day moving average | $11.12 |
| Wall St. target price | $32.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-22.06 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.37 from 2024-07-22
| 1 week (2024-07-17) | 0.30% |
|---|---|
| 1 month (2024-06-24) | 11.59% |
| 3 months (2024-04-24) | -5.34% |
| 6 months (2024-01-24) | -67.38% |
| 1 year (2023-07-24) | 953.13% |
|---|---|
| 2 years (2022-07-22) | 1,173.62% |
| 3 years (2021-07-23) | 81.18% |
| 5 years (2019-07-24) | 149.63% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -44.58% |
| Return on equity TTM | -75.66% |
| Profit margin | 0% |
| Book value | $6.35 |
| Market Capitalization | $6.7 million |
TTM: trailing 12 months
We're not expecting Tenax Therapeutics to pay a dividend over the next 12 months.
Tenax Therapeutics's shares were split on a 1:80 basis on 2 January 2024. So if you had owned 80 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tenax Therapeutics shares – just the quantity. However, indirectly, the new 7900% higher share price could have impacted the market appetite for Tenax Therapeutics shares which in turn could have impacted Tenax Therapeutics's share price.
Over the last 12 months, Tenax Therapeutics's shares have ranged in value from as little as $2.77 up to $57.576. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tenax Therapeutics's is 2.195. This would suggest that Tenax Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.